Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Monopar Therapeutics Inc. (MNPR) had Stock-Based Compensation of $4.84M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-13.72M |
|
-- |
|
-- |
|
$16.70M |
|
$-16.70M |
|
$2.99M |
|
$-13.72M |
|
$-13.72M |
|
$-13.72M |
|
$-13.72M |
|
$-13.72M |
|
$-13.72M |
|
$-16.70M |
|
$-17.42M |
|
7.41M |
|
7.41M |
|
$-1.85 |
|
$-1.85 |
|
| Balance Sheet Financials | |
$140.46M |
|
-- |
|
$0.25M |
|
$140.72M |
|
$2.74M |
|
-- |
|
$0.15M |
|
$2.89M |
|
$137.83M |
|
$137.83M |
|
$137.83M |
|
6.69M |
|
| Cash Flow Statement Financials | |
$-12.20M |
|
$-63.45M |
|
$91.57M |
|
$45.82M |
|
$61.83M |
|
$16.02M |
|
|
Stock-Based Compensation |
$4.84M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
51.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.20M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.95% |
|
-9.95% |
|
-9.75% |
|
-9.95% |
|
$20.60 |
|
$-1.65 |
|
$-1.65 |
|